晶泰控股-P(02228)今日盘中大涨9.02%,引发市场关注。据悉,该公司近期宣布与新加坡国立癌症中心及杜克-新加坡国立大学医学院开展AI新药发现合作,这成为公司股价大涨的主因。
合作中,晶泰控股将运用自身的AI多肽研发设计平台,针对新加坡方面提供的针对肾透明细胞癌的全新药物靶点,发现并设计临床候选药物。未来如研发成功,晶泰控股可与合作伙伴分享后续商业化收益。
晶泰科技创新官赖力鹏表示,公司AI药物研发技术经验丰富。结合新加坡伙伴的基础和临床研究成果,相信可为该罕见癌症开发出具有潜力的创新药物,市场前景广阔。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.